Michael J. Fox Foundation for Parkinson's Research   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: New York City NY United States (2000)

Organization Overview

First Clinical Trial
2006
NCT00461942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Fox (Michael J.) Foundation for Parkinson's Research | Ken Marek, MD | Michael J. Fox Foundation for Parkinson's Research | The Michael J. Fox Foundation for Parkinson's Research

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 2)

Constipation (Phase 2)

Dementia (Phase 2)

Disease (Phase 4)

Disease Progression (Phase 1)

Disruptive, Impulse Control, and Conduct Disorders (Phase 4)

Dyskinesia, Drug-Induced (Phase 2)

Dyskinesias (Phase 4)

Gastroparesis (Phase 1)

Helicobacter Infections (Phase 3)

Parkinson Disease (Phase 4)

Sialorrhea (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial APIs: 40